Association of clinical features and ICD
| ICD + (n: 91) | ICD − (n: 142) | p (univariant) | p (multivariant regression analysis) | |
|---|---|---|---|---|
| Male | 62 (68.1) | 83 (58.5) | 0.1370 (NS) | – |
| Age (years) | 63.9±9.3 | 67.3±9.7 | 0.0084 | p=0.028, OR 0.96, 95% CI 0.93 to 0.99 |
| Total UPDRS | 30.2±13.4 | 29.6±12.9 | 0.7293 (NS) | NS |
| UPDRS III | 20.2±9.2 | 20.3±9.2 | 0.9423 (NS) | NS |
| Fluctuations | 39 (42.9) | 57 (40.1) | 0.6811 (NS) | – |
| Exposure time (years) | 6.1±4.4 | 5.8±3.9 | 0.6024 (NS) | NS |
| Oral DA | 84 (92.3) | 113 (79.6) | 0.0087 | p=0.014, OR 3.14 (95% CI 1.26 to 7.83) |
| Transdermal DA | 7 (7.7) | 29 (20.4) | ||
| DA-LEDD (mg) | 207.5±89.2 | 198.55±96 | 0.4770 (NS) | – |
| LD-LEDD (mg) | 617.1±337 | 591.3±307. | 0.6078 (NS) | – |
| MAOI: | 67 (76.6) | 87 (61.3) | 0.0519 (NS) | – |
| Rasagiline | 66 (72.5) | 82 (57.8) | 0.0222 | p=0.032, OR 2.12, 95% CI 1.07–4.21 |
| Selegiline | 1 (1.1) | 5 (3.7) | 0.2548 (NS) | |
| Amantadine | 7 (7.7) | 8 (5.6) | 0.5322 (NS) | – |
| TOTAL LEDD (mg) | 707.6±433 | 734.2±416.4 | 0.6401 (NS) | – |
Data are shown as number and percentage for qualitative variables and mean±SD for quantitative variables.
DA-LEDD, dopamine agonist levodopa equivalent daily dose; ICD, impulse control disorder; MAOI, monoaminooxidase-B inhibitor; UPDRS, Unified Parkinson's Disease Rating Scale.